MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Amphastar Pharmaceuticals Long Term Debt Current 2011-2026 | AMPH
Annual Long Term Debt Current Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.93 M | 6.8 M | 3.91 M | 3 M | 2.98 M | 3.36 M | 3.18 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.93 M | 2.98 M | 4.45 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Cabaletta Bio
CABA
|
3.46 M | $ 3.35 | 2.61 % | $ 337 M |  USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.08 | 0.98 % | $ 5.07 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 335.44 | -1.17 % | $ 43.9 B | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.73 | 3.04 % | $ 8.97 B |  Australia |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Aligos Therapeutics
ALGS
|
3.58 M | $ 7.34 | -16.02 % | $ 72.6 M | USA |
 |
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | USA |
 |
Esperion Therapeutics
ESPR
|
2.1 M | $ 2.08 | 1.22 % | $ 432 M | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Evogene Ltd.
EVGN
|
716 K | $ 0.83 | 1.6 % | $ 27.9 M | Israel |
|
Forte Biosciences
FBRX
|
416 K | $ 32.17 | -0.77 % | $ 417 M | USA |
 |
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
1.73 M | $ 29.04 | 0.55 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
26 M | $ 29.21 | 0.5 % | $ 18.7 B |  Danmark |
 |
GT Biopharma
GTBP
|
58 K | $ 0.38 | -3.06 % | $ 2.1 M | USA |
 |
BioNTech SE
BNTX
|
45 M | $ 99.45 | 1.06 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Hoth Therapeutics
HOTH
|
5.68 K | $ 0.7 | 7.77 % | $ 9.66 M | USA |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M |  Canada |
 |
Harmony Biosciences Holdings
HRMY
|
1.07 M | $ 29.41 | 0.41 % | $ 1.69 B | USA |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.55 | -0.96 % | $ 399 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
ImmuCell Corporation
ICCC
|
85.5 K | $ 7.71 | -0.26 % | $ 69.6 M | USA |
 |
Aquestive Therapeutics
AQST
|
631 K | $ 4.2 | 1.08 % | $ 449 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.55 | -2.17 % | $ 3.12 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.47 | -1.01 % | $ 391 M |  Britain |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
|
Immatics N.V.
IMTX
|
1.88 M | $ 10.91 | -0.41 % | $ 686 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Incyte Corporation
INCY
|
5.7 M | $ 97.66 | -0.04 % | $ 19.1 B | USA |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |